Abstract 5992: Cells rapidly adapt to CDK2 inhibitors via plasticity of the CDK2/4/6-Rb-E2F axis

• Published in: Cancer research (Chicago, Ill.) Vol. 83; no. 7_Supplement; p. 5992
• Main Authors: Arora, Mansi, Moser, Justin, Hoffman, Timothy E., Watts, Lotte P., Min, Mingwei, Musteanu, Monica, Rong, Yao, Schneider, Jordan, Ill, C Ryland, Nangia, Varuna, Sanclemente, Manuel, Lapek, John, Nguyen, Lisa, Niessen, Sherry, Dann, Stephen, van Arsdale, Todd, Barbacid, Mariano, Miller, Nichol, Spencer, Sabrina L.
• Format: Journal Article
• Language: English
• Published: 04.04.2023

Abstract CDK2 is a core cell-cycle enzyme that phosphorylates a variety of substrates to drive progression through the cell cycle. CDK2 is hyperactivated in multiple cancers and is therefore an attractive therapeutic target. Here, application of a novel small molecule CDK2/4/6 inhibitor, PF-06873600...